Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.

von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, Calmy A, Bernasconi E, Böni J, Aubert V, Günthard HF, Bucher HC, Glass TR; Swiss HIV Cohort Study.

PLoS One. 2013 Oct 16;8(10):e77691. doi: 10.1371/journal.pone.0077691. eCollection 2013.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

4.

Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.

Mtambo A, Chan K, Shen A, Lima V, Hogg R, Montaner J, Moore D.

HIV Med. 2012 Mar;13(3):141-7. doi: 10.1111/j.1468-1293.2011.00950.x. Epub 2011 Nov 22.

5.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
6.

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.

Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test.

Antivir Ther. 2006;11(5):553-60.

PMID:
16964822
7.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
9.

Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.

Gardner EM, Melendez AG, Astiz M, Bray K.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):34-9. doi: 10.1177/1545109711422124. Epub 2011 Oct 4.

PMID:
21972263
10.

HIV drug resistance tendencies in Latvia.

Kolupajeva T, Aldins P, Guseva L, Dusacka D, Sondore V, Viksna L, Rozentale B.

Cent Eur J Public Health. 2008 Sep;16(3):138-40.

11.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

12.

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort.

Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7.

PMID:
19669091
13.

Response to antiretroviral treatment after failure of NNRTI plus NRTIs-based therapy. Data from the ARCA collaborative group.

Seminari E, De Silvestri A, Meini G, Callegaro A, Boeri E, Punzi G, Gianotti N, Bruzzone B, Tinelli C, Grossi P.

Curr HIV Res. 2012 Jun;10(4):334-40.

PMID:
22591356
14.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

15.

Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.

Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):68-74.

PMID:
16340476
16.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
17.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
18.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, Elegba O, Ndembi N, Abimiku A, Carr JK, Eyzaguirre LM, Blattner WA.

AIDS. 2013 Feb 20;27(4):553-61. doi: 10.1097/QAD.0b013e32835b0f59.

PMID:
23079810
19.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
20.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390

Supplemental Content

Support Center